Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
For people with relapsed or refractory diffuse large B-cell lymphoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
It is the first autotaxin inhibitor to be investigated in cancer patients
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
